STF2 Antibody

What is STF2 Antibody and what is its molecular target?

STF2 antibody targets Salmonella typhimurium flagellin, which functions as a TLR5 ligand in immunological research. STF2.4xM2e (VAX102) is a recombinant fusion protein that links four tandem copies of the M2e antigen to S. typhimurium flagellin, demonstrating its importance as a TLR5 ligand used as an adjuvant in vaccine development . This antibody can recognize both native and denatured forms of the protein, making it versatile for multiple experimental applications. Western blotting analyses with STF1/STF2 antibody have been performed to investigate protein degradation in plant research contexts , showing its utility across diverse research fields.

What are the primary research applications for STF2 antibody?

The STF2 antibody serves multiple functions in research settings:

Notably, STF2 has been utilized in vaccine development, where it serves as a built-in adjuvant through TLR5 activation . In clinical studies, STF2-based constructs have demonstrated the ability to induce antibody responses to previously non-immunogenic epitopes, highlighting its potential in novel immunotherapeutics.

How should I optimize Western blotting protocols using STF2 antibody?

When performing Western blotting with STF2 antibody, researchers should implement the following methodological approach:

• Sample preparation: Include protease inhibitors during extraction to prevent degradation of the target protein

• Protein loading: Load 20-50 μg of total protein per lane for cell lysates

• Transfer conditions: Use PVDF membranes for optimal protein binding

• Blocking: 5% non-fat dry milk in TBST (TBS with 0.1% Tween-20) for 1 hour at room temperature

• Primary antibody incubation: Dilute STF2 antibody 1:1000 in blocking solution, incubate overnight at 4°C

• Washing: 3 × 10 minutes with TBST

• Secondary antibody: Use HRP-conjugated anti-species antibody at 1:5000 dilution

• Detection: ECL reagent with appropriate exposure time optimization

Western blotting has been successfully employed to investigate protein degradation using STF1/STF2 antibody , confirming its efficacy in this application.

What controls should be included when validating STF2 antibody specificity?

Proper validation requires multiple controls:

• Positive control: Samples known to express the target protein (e.g., recombinant STF2 or cells expressing flagellin)

• Negative control: Samples lacking target expression

• Peptide competition assay: Pre-incubation of antibody with immunizing peptide should abolish specific signal

• Molecular weight verification: Confirming band size corresponds to expected molecular weight

• Multiple antibody validation: Compare results with antibodies targeting different epitopes when available

This comprehensive validation approach ensures reliable results, particularly important when studying fusion proteins like STF2.4xM2e where proper folding and epitope accessibility may affect antibody recognition .

How can STF2 antibody be utilized in TLR5 signaling pathway research?

STF2 antibody offers valuable insights into TLR5 signaling due to flagellin's role as a TLR5 ligand . Methodological approaches include:

• Protein localization studies: Immunofluorescence to track flagellin binding to TLR5 receptors

• Co-immunoprecipitation: Identify protein interactions in the TLR5 signaling cascade

• Pathway activation monitoring: Western blot analysis of downstream signaling molecules (NF-κB, MAPK)

• Quantitative assays: ELISA to measure cytokine production following TLR5 activation

• Reporter assays: Using TLR5-responsive promoters to measure activation

Understanding these pathways has direct applications in vaccine development, as demonstrated in clinical trials where STF2-based constructs activate innate immunity through TLR5 signaling .

What are the technical considerations for using STF2 antibody in multi-color flow cytometry?

Implementing STF2 antibody in multi-color flow cytometry requires careful optimization:

• Fluorophore selection: Choose conjugates with minimal spectral overlap with other channels

• Titration experiments: Determine optimal antibody concentration (typically starting at 1:100)

• Fixation protocol: Optimize to maintain epitope accessibility (typically 2-4% paraformaldehyde)

• Permeabilization: If detecting intracellular targets, use 0.1% saponin or 0.1% Triton X-100

• Compensation matrix: Include single-color controls for each fluorophore

• FMO controls (Fluorescence Minus One): Essential for accurate gating

This methodological approach ensures reliable detection of STF2 alongside other markers in complex immunological studies.

What are common causes of false negatives when using STF2 antibody and how can they be addressed?

Several factors can contribute to false negative results:

These methodological adjustments can significantly improve detection sensitivity, particularly in complex samples where target protein may be present at low concentrations.

How can background signals be reduced when using STF2 antibody in immunostaining?

High background is a common challenge that can be addressed through multiple approaches:

• Optimize blocking: Extend blocking time to 2 hours using 5% normal serum from the same species as the secondary antibody

• Increase washing stringency: Add 0.3% Triton X-100 to washing buffer

• Titrate antibody: Test serial dilutions to identify optimal concentration

• Pre-absorb primary antibody: Incubate with non-specific proteins to remove cross-reactive antibodies

• Reduce secondary antibody concentration: Typically 1:1000-1:5000 dilution

• Include protein-based carrier: Add 1% BSA to antibody dilution buffer

These optimization steps are particularly important when working with tissue samples where non-specific binding can obscure specific signals.

How has STF2 been utilized in influenza vaccine research and what are the key findings?

STF2 has played a significant role in novel influenza vaccine development:

STF2.4xM2e (VAX102) is a recombinant fusion protein linking four tandem copies of the M2e antigen to Salmonella typhimurium flagellin, which functions as a TLR5 ligand with adjuvant-like activity . In clinical studies:

• Safety profile: VAX102 was safe at 0.3 and 1.0 μg doses in healthy adults

• Immunogenicity: Induced high antibody levels to M2e at these doses

• Novel mechanism: Successfully induced antibody responses to a previously non-immunogenic, highly-conserved portion of influenza virus

• Dose-dependent effects: Initial higher doses (10 μg) showed reactogenicity, leading to evaluation of lower doses (0.03-3 μg)

• Adjuvant activity: The TLR5 ligand (flagellin) provided adjuvant-like activity through activation of innate immunity

This research demonstrates how STF2 antibody can be used to verify expression, structure, and processing of such fusion proteins in vaccine development.

What advantages does the STF2-based vaccine approach offer compared to traditional methods?

The STF2.4xM2e approach represents a significant innovation in vaccine technology:

Clinical data showed that this approach successfully induced fourfold rises in antibody levels to the M2e protein in humans, validating the concept of using flagellin fusion proteins as immunostimulatory platforms .

How can STF2 antibody be integrated with bispecific antibody technologies?

Bispecific antibody (BsAb) technologies offer interesting possibilities for STF2 research:

• Dual-targeting approaches: Combining STF2 recognition with binding to a second target (such as immune effector cells)

• Platform compatibility: STF2 epitopes could be incorporated into various BsAb platforms, including:

  • Controlled Fab-arm exchange (cFAE) technology as used in the Duobody platform

  • Dual Action Fab (DAF) platform which allows a single antibody to simultaneously bind two targets

  • Orthogonal Fab interface approach which enables preferential alignment of different Fab domains

• Applications: Such constructs could potentially:

  • Direct immune responses to flagellin-expressing pathogens

  • Create novel immunotherapeutics combining TLR5 activation with other mechanisms

  • Develop improved diagnostic tools with enhanced specificity

What methodological considerations apply when combining STF2 antibody with imaging techniques?

When integrating STF2 antibody with advanced imaging approaches, researchers should consider:

• For fluorescence microscopy:

  • Select fluorophores with appropriate spectral properties

  • Optimize fixation protocols to preserve epitope structure

  • Use appropriate mounting media to prevent photobleaching

• For immuno-PET applications (similar to those described for anti-CEA antibodies ):

  • Consider labeling with appropriate radioisotopes (e.g., 68Ga)

  • Optimize molar doses and intervals between components

  • Monitor pharmacokinetics and biodistribution

• Quantification methods:

  • Establish appropriate regions of interest

  • Measure target-to-background ratios

  • Calculate parameters such as SUVmax (maximum standardized uptake value) for quantitative comparison

These approaches enable precise localization and quantification of target proteins in complex biological systems.

What emerging applications of STF2 antibody show promise in immunological research?

Several innovative applications are emerging:

• Cancer immunotherapy: Exploring flagellin's immunostimulatory properties combined with tumor-targeting approaches

• Mucosal immunity: Investigating STF2's potential in enhancing mucosal immune responses

• Autoimmune disease modeling: Studying TLR5 activation in autoimmune contexts

• Next-generation adjuvants: Developing refined flagellin derivatives with optimized immunostimulatory profiles

• Combination therapies: Integrating STF2-based approaches with checkpoint inhibitors or other immunomodulators

These approaches leverage the well-characterized TLR5-activating properties of STF2 while exploring new therapeutic contexts.

How might advanced protein engineering enhance STF2 antibody applications?

Protein engineering offers several avenues to enhance STF2 antibody utility:

• Epitope grafting: Incorporating immunogenic epitopes from other pathogens onto the flagellin scaffold

• Affinity maturation: Enhancing binding properties through directed evolution

• Humanization: Reducing immunogenicity for therapeutic applications

• Domain engineering: Creating optimized fragments with enhanced stability or reduced toxicity

• Site-specific conjugation: Developing precisely modified versions for specialized applications

Such engineering approaches could extend the versatility of STF2-based research tools and therapeutic candidates beyond current applications.